Kazia Therapeutics doses first patient in PNOC035 study
Kazia Therapeutics says its first patient was dosed in PNOC035, a clinical study evaluating paxalisib for recurrent pediatric AT/RT brain cancer.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.